472 related articles for article (PubMed ID: 28432648)
1. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
Mandalà M; Tondini C; Merelli B; Massi D
Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
[TBL] [Abstract][Full Text] [Related]
2. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
4. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB; Postow MA
Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
8. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
[TBL] [Abstract][Full Text] [Related]
9. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
10. First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
Printz C
Cancer; 2018 Mar; 124(6):1097-1098. PubMed ID: 29509327
[No Abstract] [Full Text] [Related]
11. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
12. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
Okuyama R
Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
14. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Rotte A
J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in combination with ipilimumab for the treatment of melanoma.
Somasundaram R; Herlyn M
Expert Rev Anticancer Ther; 2015; 15(10):1135-41. PubMed ID: 26402246
[TBL] [Abstract][Full Text] [Related]
16. [Immune checkpoint‑targeted cancer immunotherapies].
Swatler J; Kozłowska E
Postepy Hig Med Dosw (Online); 2016 Jan; 70():25-42. PubMed ID: 26864062
[TBL] [Abstract][Full Text] [Related]
17. Current status of immunotherapy.
Suzuki S; Ishida T; Yoshikawa K; Ueda R
Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
[TBL] [Abstract][Full Text] [Related]
18. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
19. [Understanding current therapies in metastatic melanoma].
Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Resistance to Immune Checkpoint Blockade.
Liu D; Jenkins RW; Sullivan RJ
Am J Clin Dermatol; 2019 Feb; 20(1):41-54. PubMed ID: 30259383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
